{"entity":{"type":"insider","cik":"0001662392","url":"/insider/0001662392","json_url":"/insider/0001662392.json","name":"Meyer Colin John","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":37,"n_filings":9,"first":"2016-06-02","last":"2023-08-17","span_basis":"filed_date"},"name_variants":[{"name":"Meyer Colin John","source":"filing","n_filings":9,"first_seen":"2016-06-02","last_seen":"2023-08-17"}],"transactions":[{"id":7954549,"accession":"0001209191-23-046294","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-046294","line_url":"/filing/0001209191-23-046294#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":596.0,"shares_display":"596","price_per_share":168.7401,"price_display":"168.74","price_state":"stated","total_value":100569.0996,"total_display":"100,569.10","shares_owned_after":81633.0,"shares_owned_after_display":"81,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-16","filed_date":"2023-08-17","scope":"insider"},{"id":7954547,"accession":"0001209191-23-046294","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-046294","line_url":"/filing/0001209191-23-046294#line-1","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2144.0,"shares_display":"2,144","price_per_share":169.0687,"price_display":"169.07","price_state":"stated","total_value":362483.2928,"total_display":"362,483.29","shares_owned_after":82229.0,"shares_owned_after_display":"82,229","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-15","filed_date":"2023-08-17","scope":"insider"},{"id":7971966,"accession":"0001209191-23-030211","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-030211","line_url":"/filing/0001209191-23-030211#line-3","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":625.0,"shares_display":"625","price_per_share":80.944,"price_display":"80.94","price_state":"stated","total_value":50590.0,"total_display":"50,590.00","shares_owned_after":78373.0,"shares_owned_after_display":"78,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-16","filed_date":"2023-05-17","scope":"insider"},{"id":7971961,"accession":"0001209191-23-030211","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-030211","line_url":"/filing/0001209191-23-030211#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4469.0,"shares_display":"4,469","price_per_share":84.7568,"price_display":"84.76","price_state":"stated","total_value":378778.1392,"total_display":"378,778.14","shares_owned_after":80137.0,"shares_owned_after_display":"80,137","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-17","scope":"insider"},{"id":7971956,"accession":"0001209191-23-030211","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-030211","line_url":"/filing/0001209191-23-030211#line-1","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1139.0,"shares_display":"1,139","price_per_share":85.7728,"price_display":"85.77","price_state":"stated","total_value":97695.2192,"total_display":"97,695.22","shares_owned_after":78998.0,"shares_owned_after_display":"78,998","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-15","filed_date":"2023-05-17","scope":"insider"},{"id":8744275,"accession":"0001209191-23-017240","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-017240","line_url":"/filing/0001209191-23-017240#line-1","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":621.0,"shares_display":"621","price_per_share":84.57,"price_display":"84.57","price_state":"stated","total_value":52517.97,"total_display":"52,517.97","shares_owned_after":84606.0,"shares_owned_after_display":"84,606","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-07","filed_date":"2023-03-08","scope":"insider"},{"id":8463001,"accession":"0001209191-23-016380","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-7","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5286.0,"shares_display":"5,286","price_per_share":87.35,"price_display":"87.35","price_state":"stated","total_value":461732.1,"total_display":"461,732.10","shares_owned_after":85227.0,"shares_owned_after_display":"85,227","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-03","filed_date":"2023-03-06","scope":"insider"},{"id":8462996,"accession":"0001209191-23-016380","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-6","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34794.0,"shares_display":"34,794","price_per_share":86.49,"price_display":"86.49","price_state":"stated","total_value":3009333.06,"total_display":"3,009,333.06","shares_owned_after":121603.0,"shares_owned_after_display":"121,603","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-06","scope":"insider"},{"id":8462993,"accession":"0001209191-23-016380","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-5","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22752.0,"shares_display":"22,752","price_per_share":85.23,"price_display":"85.23","price_state":"stated","total_value":1939152.96,"total_display":"1,939,152.96","shares_owned_after":156397.0,"shares_owned_after_display":"156,397","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-06","scope":"insider"},{"id":8462990,"accession":"0001209191-23-016380","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-4","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19099.0,"shares_display":"19,099","price_per_share":87.55,"price_display":"87.55","price_state":"stated","total_value":1672117.45,"total_display":"1,672,117.45","shares_owned_after":102504.0,"shares_owned_after_display":"102,504","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-06","scope":"insider"},{"id":8462987,"accession":"0001209191-23-016380","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-3","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11181.0,"shares_display":"11,181","price_per_share":88.5,"price_display":"88.50","price_state":"stated","total_value":989518.5,"total_display":"989,518.50","shares_owned_after":91323.0,"shares_owned_after_display":"91,323","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-06","scope":"insider"},{"id":8462985,"accession":"0001209191-23-016380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-016380","line_url":"/filing/0001209191-23-016380#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Innovation Officer)","officer_title":"Chief Innovation Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":810.0,"shares_display":"810","price_per_share":90.58,"price_display":"90.58","price_state":"stated","total_value":73369.8,"total_display":"73,369.80","shares_owned_after":90513.0,"shares_owned_after_display":"90,513","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-06","scope":"insider"},{"id":4425421,"accession":"0001209191-21-040884","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-13","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12518.0,"shares_display":"12,518","price_per_share":142.0762,"price_display":"142.08","price_state":"stated","total_value":1778509.8716,"total_display":"1,778,509.87","shares_owned_after":30067.0,"shares_owned_after_display":"30,067","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425418,"accession":"0001209191-21-040884","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-12","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8867.0,"shares_display":"8,867","price_per_share":142.8332,"price_display":"142.83","price_state":"stated","total_value":1266501.9844,"total_display":"1,266,501.98","shares_owned_after":21200.0,"shares_owned_after_display":"21,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425413,"accession":"0001209191-21-040884","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-11","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6494.0,"shares_display":"6,494","price_per_share":141.0923,"price_display":"141.09","price_state":"stated","total_value":916253.3962,"total_display":"916,253.40","shares_owned_after":42585.0,"shares_owned_after_display":"42,585","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425411,"accession":"0001209191-21-040884","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-10","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4107.0,"shares_display":"4,107","price_per_share":139.9779,"price_display":"139.98","price_state":"stated","total_value":574889.2353,"total_display":"574,889.24","shares_owned_after":49079.0,"shares_owned_after_display":"49,079","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425408,"accession":"0001209191-21-040884","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-9","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3814.0,"shares_display":"3,814","price_per_share":139.1354,"price_display":"139.14","price_state":"stated","total_value":530662.4156,"total_display":"530,662.42","shares_owned_after":53186.0,"shares_owned_after_display":"53,186","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425404,"accession":"0001209191-21-040884","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-8","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2483.0,"shares_display":"2,483","price_per_share":143.9818,"price_display":"143.98","price_state":"stated","total_value":357506.8094,"total_display":"357,506.81","shares_owned_after":18717.0,"shares_owned_after_display":"18,717","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425400,"accession":"0001209191-21-040884","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-7","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1217.0,"shares_display":"1,217","price_per_share":145.1089,"price_display":"145.11","price_state":"stated","total_value":176597.5313,"total_display":"176,597.53","shares_owned_after":17500.0,"shares_owned_after_display":"17,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425397,"accession":"0001209191-21-040884","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-6","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":145.9197,"price_display":"145.92","price_state":"stated","total_value":72959.85,"total_display":"72,959.85","shares_owned_after":17000.0,"shares_owned_after_display":"17,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-15","filed_date":"2021-06-16","scope":"insider"},{"id":4425394,"accession":"0001209191-21-040884","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-5","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12615.0,"shares_display":"12,615","price_per_share":143.5395,"price_display":"143.54","price_state":"stated","total_value":1810750.7925,"total_display":"1,810,750.79","shares_owned_after":64385.0,"shares_owned_after_display":"64,385","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider"},{"id":4425391,"accession":"0001209191-21-040884","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-4","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4225.0,"shares_display":"4,225","price_per_share":144.4434,"price_display":"144.44","price_state":"stated","total_value":610273.365,"total_display":"610,273.36","shares_owned_after":60160.0,"shares_owned_after_display":"60,160","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider"},{"id":4425386,"accession":"0001209191-21-040884","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-3","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2760.0,"shares_display":"2,760","price_per_share":145.4856,"price_display":"145.49","price_state":"stated","total_value":401540.256,"total_display":"401,540.26","shares_owned_after":57400.0,"shares_owned_after_display":"57,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider"},{"id":4425381,"accession":"0001209191-21-040884","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-040884","line_url":"/filing/0001209191-21-040884#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":146.15,"price_display":"146.15","price_state":"stated","total_value":58460.0,"total_display":"58,460.00","shares_owned_after":57000.0,"shares_owned_after_display":"57,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider"},{"id":2560020,"accession":"0001209191-20-059079","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-12","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2450.0,"shares_display":"2,450","price_per_share":164.4439,"price_display":"164.44","price_state":"stated","total_value":402887.555,"total_display":"402,887.56","shares_owned_after":75945.0,"shares_owned_after_display":"75,945","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-18","scope":"insider"},{"id":2560012,"accession":"0001209191-20-059079","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-11","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1930.0,"shares_display":"1,930","price_per_share":166.1364,"price_display":"166.14","price_state":"stated","total_value":320643.252,"total_display":"320,643.25","shares_owned_after":72200.0,"shares_owned_after_display":"72,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-18","scope":"insider"},{"id":2560005,"accession":"0001209191-20-059079","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-10","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1815.0,"shares_display":"1,815","price_per_share":165.2463,"price_display":"165.25","price_state":"stated","total_value":299922.0345,"total_display":"299,922.03","shares_owned_after":74130.0,"shares_owned_after_display":"74,130","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-18","scope":"insider"},{"id":2560000,"accession":"0001209191-20-059079","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-9","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":170.59,"price_display":"170.59","price_state":"stated","total_value":34118.0,"total_display":"34,118.00","shares_owned_after":72000.0,"shares_owned_after_display":"72,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-18","scope":"insider"},{"id":2559992,"accession":"0001209191-20-059079","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-7","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12174.0,"shares_display":"12,174","price_per_share":170.4778,"price_display":"170.48","price_state":"stated","total_value":2075396.7372,"total_display":"2,075,396.74","shares_owned_after":78431.0,"shares_owned_after_display":"78,431","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2559988,"accession":"0001209191-20-059079","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-6","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3824.0,"shares_display":"3,824","price_per_share":171.3826,"price_display":"171.38","price_state":"stated","total_value":655367.0624,"total_display":"655,367.06","shares_owned_after":74607.0,"shares_owned_after_display":"74,607","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2559980,"accession":"0001209191-20-059079","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-5","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2207.0,"shares_display":"2,207","price_per_share":172.6065,"price_display":"172.61","price_state":"stated","total_value":380942.5455,"total_display":"380,942.55","shares_owned_after":72400.0,"shares_owned_after_display":"72,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2559975,"accession":"0001209191-20-059079","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-4","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":174.98,"price_display":"174.98","price_state":"stated","total_value":34996.0,"total_display":"34,996.00","shares_owned_after":72100.0,"shares_owned_after_display":"72,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2559970,"accession":"0001209191-20-059079","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-3","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":175.0,"price_display":"175.00","price_state":"stated","total_value":17500.0,"total_display":"17,500.00","shares_owned_after":72000.0,"shares_owned_after_display":"72,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2559964,"accession":"0001209191-20-059079","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-059079","line_url":"/filing/0001209191-20-059079#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":173.75,"price_display":"173.75","price_state":"stated","total_value":17375.0,"total_display":"17,375.00","shares_owned_after":72300.0,"shares_owned_after_display":"72,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-16","filed_date":"2020-11-18","scope":"insider"},{"id":2588752,"accession":"0001209191-20-057734","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-057734","line_url":"/filing/0001209191-20-057734#line-1","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Research Officer)","officer_title":"Chief Research Officer","security_title":"Class A common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":175.0,"price_display":"175.00","price_state":"stated","total_value":4375000.0,"total_display":"4,375,000.00","shares_owned_after":72000.0,"shares_owned_after_display":"72,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-09","filed_date":"2020-11-10","scope":"insider"},{"id":2701848,"accession":"0001209191-16-137425","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-137425","line_url":"/filing/0001209191-16-137425#line-1","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer (Chief Medical Officer)","officer_title":"Chief Medical Officer","security_title":"Class A common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7000.0,"shares_display":"7,000","price_per_share":16.26,"price_display":"16.26","price_state":"stated","total_value":113820.0,"total_display":"113,820.00","shares_owned_after":27172.0,"shares_owned_after_display":"27,172","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-16","filed_date":"2016-08-17","scope":"insider"},{"id":2937419,"accession":"0000899243-16-021416","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-021416","line_url":"/filing/0000899243-16-021416#line-2","is_derivative":false,"issuer_cik":"0001358762","issuer_name":"REATA PHARMACEUTICALS INC","issuer_ticker":"RETA","issuer_name_source":null,"issuer_url":"/issuer/0001358762","owner_cik":"0001662392","owner_name":"Meyer Colin John","owner_url":"/insider/0001662392","role":"Officer","officer_title":"See Remarks","security_title":"Class A common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":110000.0,"total_display":"110,000.00","shares_owned_after":20172.0,"shares_owned_after_display":"20,172","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-06-01","filed_date":"2016-06-02","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":37,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":35,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":37},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001358762","name":"REATA PHARMACEUTICALS INC","url":"/issuer/0001358762","role":"Officer (Chief Innovation Officer)","n_filings":9,"first_seen":"2016-06-02","last_seen":"2023-08-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001662392","retrieved_at":"2026-08-21T06:05:49+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}